Nippon Shinyaku develops antisense drug against Duchenne and Fukuyama muscular dystrophy

Nippon Shinyaku had developed long-strand DNA synthesis in the late 1990ies and started collaboration with the National Center for Mental and Neurological Medicine to develop an antisense RNA (NS-065/NCNP-01) with exon skipping action against DMD. The synthetic double-stranded RNA polyI: polyC is prepared using a novel RNA synthesis method (2-cyanoethoxymethyl or CEM method) and delivered with cationic liposomes. Physician-initiated trials are underway in Japan and the USA.

Nippon Shinyaku report 2017

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny